Table 2.
Characteristics of patients in the oxaliplatin and cisplatin groups before and after propensity-score weighting
| Characteristic | Before weighting | After weighting | ||||
|---|---|---|---|---|---|---|
| Oxaliplatin | Cisplatin | SMD | Oxaliplatin | Cisplatin | SMD | |
| n | 90 | 152 | 35.3 | 35.3 | ||
| Mean age (standard deviation) | 76.4 (4.16) | 75.4 (4.02) | 0.24 | 76.0 (4.19) | 76.0 (4.15) | < 0.001 |
| Sex = Female (%) | 32 (35.6) | 34 (22.4) | 0.29 | 10.7 (30.5) | 10.7 (30.5) | < 0.001 |
| Region = Tochigi prefecture (%) | 20 (22.2) | 46 (30.3) | 0.18 | 10.8 (30.6) | 10.8 (30.6) | < 0.001 |
| ATC classification system | ||||||
| Alimentary tract and metabolism (%) | 90 (100.0) | 150 (98.7) | 0.16 | 35.3 (100.0) | 35.3 (100.0) | < 0.001 |
| Blood and blood-forming organs (%) | 90 (100.0) | 151 (99.3) | 0.12 | 35.3 (100.0) | 35.3 (100.0) | < 0.001 |
| Cardiovascular system (%) | 74 (82.2) | 116 (76.3) | 0.15 | 30.4 (86.1) | 30.4 (86.1) | < 0.001 |
| Dermatological (%) | 33 (36.7) | 51 (33.6) | 0.07 | 13.3 (37.8) | 13.3 (37.8) | < 0.001 |
| Genitourinary system and sex hormones (%) | 15 (16.7) | 17 (11.2) | 0.16 | 5.1 (14.5) | 5.1 (14.5) | < 0.001 |
| Systemic hormonal preparations, excluding sex hormones and insulin (%) | 90 (100.0) | 82 (53.9) | 1.31 | 35.3 (100.0) | 35.3 (100.0) | < 0.001 |
| Anti-infective (systemic use) (%) | 53 (58.9) | 94 (61.8) | 0.06 | 21.9 (62.1) | 21.9 (62.1) | < 0.001 |
| Musculo-skeletal system (%) | 64 (71.1) | 113 (74.3) | 0.07 | 26.4 (74.8) | 26.4 (74.8) | < 0.001 |
| Nervous system (%) | 88 (97.8) | 146 (96.1) | 0.10 | 34.2 (97.1) | 34.2 (97.1) | < 0.001 |
| Antiparasitic products, insecticides, and repellents (%) | 78 (86.7) | 125 (82.2) | 0.12 | 30.3 (85.8) | 30.3 (85.8) | < 0.001 |
| Respiratory system (%) | 47 (52.2) | 59 (38.8) | 0.28 | 18.4 (52.3) | 18.4 (52.3) | < 0.001 |
| Sensory organs (%) | 31 (34.4) | 40 (26.3) | 0.18 | 11.0 (31.2) | 11.0 (31.2) | < 0.001 |
| Various (%)a | 90 (100.0) | 148 (97.4) | 0.23 | 35.3 (100.0) | 34.6 (98.0) | 0.20 |
| Comorbiditiesb | ||||||
| Myocardial infarction (%) | 3 (3.3) | 12 (7.9) | 0.20 | 1.5 (4.2) | 1.5 (4.2) | < 0.001 |
| Congestive heart failure (%) | 18 (20.0) | 35 (23.0) | 0.07 | 6.7 (19.1) | 6.7 (19.1) | < 0.001 |
| Peripheral vascular disease (%) | 8 (8.9) | 21 (13.8) | 0.16 | 4.4 (12.5) | 4.4 (12.5) | < 0.001 |
| Cerebrovascular disease (%) | 11 (12.2) | 21 (13.8) | 0.05 | 4.9 (14.0) | 4.9 (14.0) | < 0.001 |
| Dementia (%) | 1 (1.1) | 0 (0.0) | 0.15 | 0.0 (0.0) | 0.0 (0.0) | < 0.001 |
| Chronic pulmonary disease (%) | 28 (31.1) | 34 (22.4) | 0.20 | 10.4 (29.5) | 10.4 (29.5) | < 0.001 |
| Rheumatic disease (%) | 1 (1.1) | 7 (4.6) | 0.21 | 0.6 (1.8) | 0.6 (1.8) | < 0.001 |
| Peptic ulcer disease (%) | 26 (28.9) | 52 (34.2) | 0.14 | 12.1 (34.2) | 12.1 (34.2) | < 0.001 |
| Mild liver disease (%) | 26 (28.9) | 54 (35.5) | 0.14 | 10.6 (30.1) | 10.6 (30.1) | < 0.001 |
| Diabetes without chronic complication (%) | 14 (15.6) | 20 (17.1) | 0.04 | 5.7 (16.2) | 5.7 (16.2) | < 0.001 |
| Diabetes with chronic complication (%) | 1 (1.1) | 8 (5.3) | 0.24 | 0.7 (1.9) | 0.7 (1.9) | < 0.001 |
| Hemiplegia or paraplegia (%) | 1 (1.1) | 2 (1.3) | 0.02 | 0.3 (0.8) | 0.3 (0.8) | < 0.001 |
| Renal disease (%) | 4 (4.4) | 3 (2.0) | 0.14 | 0.8 (2.2) | 0.8 (2.2) | < 0.001 |
| Moderate or severe liver disease (%) | 1 (1.1) | 0 (0.0) | 0.15 | 0.0 (0.0) | 0.0 (0.0) | < 0.001 |
| Metastatic solid tumor (%) | 65 (72.2) | 120 (78.9) | 0.16 | 27.6 (78.2) | 27.6 (78.2) | < 0.001 |
| AIDS/HIV (%) | 90 (100.0) | 152 (100.0) | < 0.001 | 35.3 (100.0) | 35.3 (100.0) | < 0.001 |
SMD standardized mean difference, ATC anatomical therapeutic chemical, AIDS acquired immunodeficiency syndrome, HIV human immunodeficiency virus. a This category was removed when calculating the propensity score. bComorbidities were according to the Charlson comorbidity index